187 patents
Page 9 of 10
Utility
Methods for Producing Preparations of Recombinant Aav Virions Substantially Free of Empty Capsids
20 May 20
Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described.
Guang QU, John Fraser WRIGHT
Filed: 11 Aug 19
Utility
Methods for Introducing Mannose 6-PHOSPHATE and Other Oligosaccharides Onto Glycoproteins and Its Application Thereof
13 May 20
Methods to introduce highly phosphorylated mannopyranosyl oligosaccharide derivatives containing mannose-6-phosphate (M6P), or other oligosaccharides bearing other terminal hexoses, to carbonyl groups on oxidized glycans of glycoproteins while retaining their biological activity are described.
Yunxiang ZHU
Filed: 11 Jun 19
Utility
Hyperglycosylated Binding Polypeptides
6 May 20
Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering.
Clark PAN, Huawei QIU, Pradeep DHAL, Bo CHEN, Diego GIANOLIO
Filed: 16 Oct 19
Utility
SCFV-FC Dimers That Bind Transforming Growth FACTOR-BETA1 with High Affinity, Avidity and Specificity
29 Apr 20
An scFv-Fc dimer binds and neutralizes TGFβ1 selectively and with high affinity and avidity.
Huawei Qiu, Clark Pan, Julie Bird
Filed: 29 Oct 19
Utility
Elution of Biomolecules from Multi-modal Resins Using Mes and Mops As Mobile Phase Modifiers
29 Apr 20
The present invention relates to methods for purifying or enriching a biomolecule using multimodal resins and an elution buffer containing a Good's buffer.
Rahul Godawat, Daniel Cummings, Veena Warikoo
Filed: 22 Dec 19
Utility
Biomarkers of Proteopathies and Uses Thereof
22 Apr 20
Provided herein are methods of determining the efficacy of a treatment for a proteopathy, diagnosing a proteopathy in a subject, determining a subject's risk of developing a proteopathy, determining the stage of a proteopathy in a subject, monitoring a proteopathy in a subject, selecting a treatment for a proteopathy for a subject, and selecting a subject for a clinical trial that include determining a level of at least one sphingolipid in a sample including a biological fluid from the subject.
Sergio Pablo Sardi, Clemens Scherzer
Filed: 23 Mar 17
Utility
VARIANT RNAi
8 Apr 20
Provided herein are RNAi molecules including a first strand containing a guide sequence and a second strand comprising a non-guide sequence where the non-guide sequence contains a bulge opposite the seed region of the guide sequences; e.g., opposite the cleavage sequence.
Lisa M. STANEK, Adam PALERMO, Brenda RICHARDS, Sergio Pablo SARDI, Catherine O'RIORDAN, Antonius SONG
Filed: 9 Sep 19
Utility
Gene Therapy for Amyotrophic Lateral Sclerosis and Other Spinal Cord Disorders
1 Apr 20
This disclosure provides methods and compositions for treating disorders or injuries that affect motor function and control in a subject.
James DODGE, Lamya SHIHABUDDIN, Catherine O'RIORDAN
Filed: 19 Aug 19
Utility
Udp Glycosyltransferase Inhibitors and Methods of Use
1 Apr 20
Sungtaek LIM, Robert H. BARKER, JR., Mary A. CROMWELL, Elina MAKINO, Bradford HIRTH, John JIANG, Sachin MANIAR, Mark MUNSON, Yong-Mi CHOI, Sukanthini THURAIRATNAM, Kwon Yon MUSICK, James PRIBISH, Michael ANGELASTRO
Filed: 30 Sep 19
Utility
Polynucleotide Agents Targeting SERPINC1 (AT3) and Methods of Use Thereof
1 Apr 20
The invention relates to polynucleotide agents targeting the Serpinc1 (AT3) gene, and methods of using such polynucleotide agents to inhibit expression of Serpinc1 and to treat subjects having a bleeding disorder, e.g., a hemophilia.
Gregory Hinkle
Filed: 12 May 19
Utility
Microcarrier Perfusion Culturing Methods and Uses Thereof
11 Mar 20
Provided herein are methods of culturing a mammalian cell and various methods that utilize these culturing methods.
Jianguo Yang, Yang Yang
Filed: 27 Aug 19
Utility
Gene Therapy for Niemann-pick Disease Type a
11 Mar 20
This disclosure pertains to methods and compositions for tolerizing a mammal's brain to exogenously administered acid sphingomyelinase polypeptide by first delivering an effective amount of a transgene encoding the polypeptide to the mammal's hepatic tissue and then administering an effective amount of the transgene to the mammal's central nervous system (CNS).
Marco A. PASSINI, Robin J. ZIEGLER, James C. DODGE, Lamya SHIHABUDDIN, Seng H. CHENG
Filed: 18 Aug 19
Utility
Sterile Chromatography Resin and Use Thereof In Manufacturing Processes
4 Mar 20
Provided herein are methods of reducing bioburden of a chromatography resin that include exposing a container including a composition including (i) a chromatography resin and (ii) a liquid including at least on alcohol to a dose of gamma-irradiation sufficient to reduce the bioburden of the container and the chromatography resin, where the at least one alcohol are present in an amount sufficient to ameliorate the loss of binding capacity of the chromatography resin after/upon exposure to the dose of gamma-irradiation.
Rohan Patil, Chad Varner
Filed: 15 Aug 19
Utility
Gene Therapy for Retinitis Pigmentosa
12 Feb 20
Provided herein are methods for treating retinitis pigmentosa using an AAV particles encoding miR-708.
Catherine O'RIORDAN, Matthew ADAMOWICZ
Filed: 2 Jul 19
Utility
Glucosylceramide Synthase Inhibitors
12 Feb 20
The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.
Elyse BOURQUE, Mario CABRERA-SALAZAR, Cassandra CELATKA, Seng CHENG, Mary A. CROMWELL, Andrew GOOD, Bradford HIRTH, Katherine JANCSICS, John P. LEONARD, Lingyun LI, James LILLIE, Hanlan LIU, Elina MAKINO, John MARSHALL, Paul MASON, Markus METZ, Fazeela MORSHED, Thomas O'SHEA, Ronald SCHEULE, Renato SKERLJ, Bing WANG, Yibin XIANG, Zhong ZHAO
Filed: 14 Aug 19
Utility
Anti-Human CD52 Immunoglobulins
5 Feb 20
The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52.
Bruce L. Roberts, Srinivas Shankara, William Harold Brondyk, William M. Siders
Filed: 9 Apr 19
Utility
Early Post-transfection Isolation of Cells (Epic) for Biologics Production
15 Jan 20
Provided herein are methods for selecting a population of cells expressing a target polypeptide.
Victor R. Cairns, Christine DeMaria, Jason Vitko
Filed: 22 Apr 19
Utility
Oligosaccharides Comprising an Aminooxy Group and Conjugates Thereof
8 Jan 20
The invention provides methods for the synthesis of oligosaccharides comprising an aminooxy group.
Yunxiang ZHU, Seng H. CHENG, Canwen JIANG, Luis Z. AVILA
Filed: 5 Feb 19
Utility
Chemokine Receptor Binding Heterocyclic Compounds with Enhanced Efficacy
1 Jan 20
The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings.
Gary J. Bridger, Renato T. Skerlj, Al Kaller, Curtis Harwig, David Bogucki, Trevor R. Wilson, Jason B. Crawford, Ernest J. McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols, Christopher Dennis Smith, Maria Rosaria Di Fluri
Filed: 9 Apr 19
Utility
Methods for Treating Osteogenesis Imperfecta
25 Dec 19
The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGFβ).
Brendan Lee, Kuber T. Sampath
Filed: 30 Jun 19